281 related articles for article (PubMed ID: 17253535)
21. Anabolic-androgenic steroids for alcoholic liver disease.
Rambaldi A; Gluud C
Cochrane Database Syst Rev; 2006 Oct; 2006(4):CD003045. PubMed ID: 17054157
[TBL] [Abstract][Full Text] [Related]
22. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Gluud LL; Vilstrup H; Morgan MY
Cochrane Database Syst Rev; 2016 Apr; 4():CD003044. PubMed ID: 27089005
[TBL] [Abstract][Full Text] [Related]
23. Glucocorticosteroids for people with alcoholic hepatitis.
Pavlov CS; Varganova DL; Casazza G; Tsochatzis E; Nikolova D; Gluud C
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD001511. PubMed ID: 29096421
[TBL] [Abstract][Full Text] [Related]
24. S-adenosyl-L-methionine for alcoholic liver diseases.
Rambaldi A; Gluud C
Cochrane Database Syst Rev; 2006 Apr; (2):CD002235. PubMed ID: 16625556
[TBL] [Abstract][Full Text] [Related]
25. Calcium supplementation commencing before or early in pregnancy, or food fortification with calcium, for preventing hypertensive disorders of pregnancy.
Hofmeyr GJ; Manyame S
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD011192. PubMed ID: 28949421
[TBL] [Abstract][Full Text] [Related]
26. Weight reduction for non-alcoholic fatty liver disease.
Peng L; Wang J; Li F
Cochrane Database Syst Rev; 2011 Jun; (6):CD003619. PubMed ID: 21678341
[TBL] [Abstract][Full Text] [Related]
27. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma.
Weis S; Franke A; Mössner J; Jakobsen JC; Schoppmeyer K
Cochrane Database Syst Rev; 2013 Dec; (12):CD003046. PubMed ID: 24357457
[TBL] [Abstract][Full Text] [Related]
28. Omega-3 fatty acid supplementation for cystic fibrosis.
Watson H; Stackhouse C
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD002201. PubMed ID: 32275788
[TBL] [Abstract][Full Text] [Related]
29. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2015 Feb; (2):CD001939. PubMed ID: 25715177
[TBL] [Abstract][Full Text] [Related]
30. Antioxidant supplements for preventing gastrointestinal cancers.
Bjelakovic G; Nikolova D; Simonetti RG; Gluud C
Cochrane Database Syst Rev; 2004 Oct; (4):CD004183. PubMed ID: 15495084
[TBL] [Abstract][Full Text] [Related]
31. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
Sato K; Gosho M; Yamamoto T; Kobayashi Y; Ishii N; Ohashi T; Nakade Y; Ito K; Fukuzawa Y; Yoneda M
Nutrition; 2015; 31(7-8):923-30. PubMed ID: 26059365
[TBL] [Abstract][Full Text] [Related]
32. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
Goh ET; Andersen ML; Morgan MY; Gluud LL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD002798. PubMed ID: 28745801
[TBL] [Abstract][Full Text] [Related]
33. Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.
Goh ET; Andersen ML; Morgan MY; Gluud LL
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD002798. PubMed ID: 28796283
[TBL] [Abstract][Full Text] [Related]
34. Ursodeoxycholic acid for primary biliary cirrhosis.
Rudic JS; Poropat G; Krstic MN; Bjelakovic G; Gluud C
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD000551. PubMed ID: 23235576
[TBL] [Abstract][Full Text] [Related]
35. Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.
Lamers MH; Broekman M; Drenth JP; Gluud C
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD011132. PubMed ID: 24937404
[TBL] [Abstract][Full Text] [Related]
36. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.
Musso G; Cassader M; Rosina F; Gambino R
Diabetologia; 2012 Apr; 55(4):885-904. PubMed ID: 22278337
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Dong Y; Lv Q; Li S; Wu Y; Li L; Li J; Zhang F; Sun X; Tong N
Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):284-295. PubMed ID: 28065744
[TBL] [Abstract][Full Text] [Related]
38. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2017 May; 5(5):CD001939. PubMed ID: 28518283
[TBL] [Abstract][Full Text] [Related]
39. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2015 Sep; (9):CD001939. PubMed ID: 26377410
[TBL] [Abstract][Full Text] [Related]
40. Antioxidants for male subfertility.
Showell MG; Mackenzie-Proctor R; Brown J; Yazdani A; Stankiewicz MT; Hart RJ
Cochrane Database Syst Rev; 2014; (12):CD007411. PubMed ID: 25504418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
